Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Publication number: 20090155284Abstract: The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4.Type: ApplicationFiled: December 2, 2008Publication date: June 18, 2009Inventors: BOLIANG CAO, George Vande Woude
-
Publication number: 20090148440Abstract: The present invention relates to antibodies and antigen-binding fragments that bind to interleukin-22 binding protein, in particular, human interleukin-22 binding protein (IL-22 BP), and are involved in regulating interleukin-22-associated biological responses. The invention also relates to methods of using the antibodies and antigen-binding fragments to treat disorders associated with interleukin-22. The antibodies disclosed herein are useful in diagnosing, preventing, or treating metabolic disorders including obesity, diabetes, hyperlipidemia and hyperinsulinemia etc.Type: ApplicationFiled: December 21, 2006Publication date: June 11, 2009Applicant: DHY & CO., LTD.Inventors: Yu Liang Huang, Xu Wen Chen, Zhi Hua Huang
-
Patent number: 7544357Abstract: The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.Type: GrantFiled: January 8, 2002Date of Patent: June 9, 2009Assignee: Baylor Research InstituteInventors: Jacques F. Banchereau, Anna Karolina Palucka, Patrick Blanco
-
Patent number: 7541160Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: November 1, 2004Date of Patent: June 2, 2009Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 7541033Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.Type: GrantFiled: January 21, 2004Date of Patent: June 2, 2009Assignee: Applied Molecular Evolution, Inc.Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
-
Patent number: 7541438Abstract: A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses thereof; and various monoclonal antibodies having various characteristics against various mammalian CTGFs useful for detecting and assaying CTGFs present in body fluids of mammals suffering from various diseases.Type: GrantFiled: January 4, 2006Date of Patent: June 2, 2009Assignee: Amgen, Inc.Inventors: Takuya Tamatani, Katsunari Tezuka, Shinji Sakamoto, Masaharu Takigawa
-
Patent number: 7537932Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: June 7, 1995Date of Patent: May 26, 2009Assignees: Schering Corporation, InsermInventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
-
Publication number: 20090131638Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.Type: ApplicationFiled: October 5, 2006Publication date: May 21, 2009Inventors: Julian Davies, Bryan Edward Jones, Andrew Ihor Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Linda Maureen O'Bryan (nee Tobias), Rong Wang
-
Patent number: 7534431Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: February 2, 2004Date of Patent: May 19, 2009Assignee: Immunomedics, Inc.Inventors: William J. McBride, Hans J. Hansen, Chien-Hsing Ken Chang, David M. Goldenberg
-
Patent number: 7534572Abstract: A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for neoplastic diseas, where detection of VEGF-D on or in a sample such as tumor cells, blood vessel endothelial cells or lymph vessel endothelial cells indicates neoplastic disease; a method for promoting and maintaining vascularization of normal tissue in an organism involving administering a vascularization promoting amount of VEGF-D or a fragment or analog thereof to the organism; a method for screening tumors for metastatic risk involving detecting expression of VEFG-D by a tumor which indicates metastatic risk; and a method of detecting micro-metastasis of neoplastic disease involving detection of VEGF-D on or in a tissue sample which indicates metastasis of a neoplastic disease.Type: GrantFiled: July 28, 2003Date of Patent: May 19, 2009Assignee: Vegenics LimitedInventors: Marc Achen, Steven Stacker
-
Patent number: 7534430Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: September 28, 2006Date of Patent: May 19, 2009Assignee: Genetics Institute, LLCInventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 7534870Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with a combination of a poloxamer polyol and a polyhydric alcohol.Type: GrantFiled: July 14, 2003Date of Patent: May 19, 2009Assignee: Lek Pharmaceuticals d.d.Inventors: Andreja Vukmirovic, Tanja Rozman Peterka, Jelka Svetek, Alenka Paris
-
Patent number: 7527790Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.Type: GrantFiled: June 11, 2002Date of Patent: May 5, 2009Assignee: Daiichi Sankyo Company, LimitedInventors: Kyoji Yamaguchi, Hisataka Yasuda, Nobuaki Nakagawa, Nobuyuki Shima, Masahiko Kinosaki, Eisuke Tsuda, Masaaki Goto, Kazuki Yano, Akihiro Tomoyasu, Fumie Kobayashi, Naohiro Washida, Ken Takahashi, Tomonori Morinaga, Kanji Higashio
-
Patent number: 7524502Abstract: The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.Type: GrantFiled: November 11, 2002Date of Patent: April 28, 2009Assignee: Merck Patent GmbHInventors: Koen Hellendoorn, Matthew Baker, Francis J. Carr
-
Patent number: 7521056Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: GrantFiled: March 28, 2006Date of Patent: April 21, 2009Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 7514079Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: GrantFiled: November 5, 2004Date of Patent: April 7, 2009Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben
-
Publication number: 20090087905Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.Type: ApplicationFiled: October 30, 2007Publication date: April 2, 2009Applicant: VEGENICS LIMITEDInventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
-
Patent number: 7510709Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.Type: GrantFiled: October 29, 2003Date of Patent: March 31, 2009Assignee: Genentech, Inc.Inventor: Austin L. Gurney
-
Publication number: 20090082550Abstract: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.Type: ApplicationFiled: August 5, 2008Publication date: March 26, 2009Inventors: Ian Tomlinson, Amrik Basran, Philip Jones
-
Publication number: 20090075341Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs.Type: ApplicationFiled: July 24, 2008Publication date: March 19, 2009Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
-
Patent number: 7504485Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: July 1, 2004Date of Patent: March 17, 2009Assignee: Abbott GmbH & Co., KGInventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Patent number: 7501497Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.Type: GrantFiled: October 3, 2005Date of Patent: March 10, 2009Assignee: ZymoGenetics, Inc.Inventors: Mark W. Rixon, Jane A. Gross
-
Patent number: 7495085Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: March 12, 2004Date of Patent: February 24, 2009Assignees: Wyeth, Cambridge Antibody Technology LimitedInventors: Viia Valge-Archer, Andrew James Williams, Deborah A. Young, Matthew J. Whitters, Mary Collins, Joann Witek
-
Publication number: 20090048432Abstract: This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.Type: ApplicationFiled: September 26, 2008Publication date: February 19, 2009Applicant: Chi Mei Medical Center of TaiwanInventor: Ming-Shi Chang
-
Patent number: 7491516Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1? ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.Type: GrantFiled: June 28, 2001Date of Patent: February 17, 2009Assignee: Abbott LaboratoriesInventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
-
Patent number: 7491802Abstract: The present invention provides an antibody (anti-BAMBI antibody) which recognizes a polypeptide having the amino acid sequence of SEQ ID No: 1 or a polypeptide having an amino acid sequence containing deletion, substitution or addition of one or more amino acids as compared to the amino acid sequence of SEQ ID No: 1, a method for manufacturing same, a therapeutic agent for colon cancer or liver cancer comprising an anti-BAMBI antibody, a diagnostic agent comprising a primer or probe for detecting the BAMBI gene, and a therapeutic agent for colon cancer or liver cancer comprising a vector which generates BAMBI dsRNA, and the like.Type: GrantFiled: May 27, 2004Date of Patent: February 17, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Tetsu Akiyama, Takashi Sekiya, Susumu Ohwada
-
Patent number: 7491391Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: June 30, 2006Date of Patent: February 17, 2009Assignee: Centocor, Inc.Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
-
Patent number: 7491804Abstract: The identification and use of two major DNA-PKcs autophosphorylation sites. Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and 52056. Peptides and polynucleotides encoding same, that feature these two sites of phosphorylation. The antibodies do not bind to the unphosphorylated DNA-PKcs protein or peptide, thus providing diagnostic tools to monitor the effectiveness of treatments which target the DNA repair pathway of cancer cells, and the ability to intervene or inhibit in phosphorylation of T2609 or 52056, either through application of a drug or an antibody, to increase the radiosensitivity of cancer cells.Type: GrantFiled: April 21, 2003Date of Patent: February 17, 2009Assignee: The Regents of the University of CaliforniaInventors: David J. Chen, Ping-Chi Benjamin Chen, Doug W. Chan
-
Patent number: 7482436Abstract: A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. The antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by IL-6.Type: GrantFiled: August 28, 2003Date of Patent: January 27, 2009Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuhisa Sugimura, Kazuyuki Yoshizaki, Toshihiro Nakashima, Takumi Sasaki
-
Publication number: 20090004199Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.Type: ApplicationFiled: April 27, 2007Publication date: January 1, 2009Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
-
Patent number: 7465547Abstract: The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.Type: GrantFiled: November 12, 2003Date of Patent: December 16, 2008Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Shoji Furusako, Kamon Shirakawa
-
Patent number: 7462696Abstract: The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods.Type: GrantFiled: October 18, 2002Date of Patent: December 9, 2008Assignee: Bayer Pharmaceutical CorporationInventors: Toshihiko Takeuchi, Nathalie Dubois-Stringfellow, John E. Murphy, Julie Rinkenberger
-
Publication number: 20080292642Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.Type: ApplicationFiled: March 27, 2008Publication date: November 27, 2008Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Patent number: 7446175Abstract: An IL-1? binding molecule, in particular an antibody to human IL-1?, especially a human antibody to human IL-1? is provided, wherein the CDRs of the heavy and light chains having amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.Type: GrantFiled: August 20, 2001Date of Patent: November 4, 2008Assignee: Novartis AGInventors: Hermann Gram, Franco E. Di Padova
-
Patent number: 7446181Abstract: The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions.Type: GrantFiled: April 6, 2004Date of Patent: November 4, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Sean A. McCarthy
-
Patent number: 7435800Abstract: Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.Type: GrantFiled: March 2, 2006Date of Patent: October 14, 2008Assignee: Chi-Mei Medical CenterInventor: Ming-Shi Chang
-
Patent number: 7435799Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: January 8, 2004Date of Patent: October 14, 2008Assignee: Applied Molecular EvolutionInventors: Jeffry D. Watkins, Alain P. Vasserot, David Marquis, William D. Huse
-
Patent number: 7431927Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: March 24, 2005Date of Patent: October 7, 2008Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Patent number: 7432360Abstract: The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol.Type: GrantFiled: June 27, 2005Date of Patent: October 7, 2008Assignee: Aventis Pharmaceuticals Inc.Inventor: Atef Gayed
-
Publication number: 20080241096Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.Type: ApplicationFiled: September 10, 2007Publication date: October 2, 2008Applicant: Amgen Inc.Inventors: John E. Sims, Blair R. Renshaw, Christopher Gabel, Jennifer E. Towne, Randal R. Ketchem
-
Publication number: 20080235814Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.Type: ApplicationFiled: October 14, 2005Publication date: September 25, 2008Inventors: Aya Jakobovits, Raju Kucherlapati, Susan Klapholz, Michael J. Mendez, Larry Green
-
Publication number: 20080234469Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: June 11, 2007Publication date: September 25, 2008Inventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 7427471Abstract: The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extra immunoglobulin domain to the constant region.Type: GrantFiled: June 5, 2003Date of Patent: September 23, 2008Assignee: Centocor, Inc.Inventors: Bernard J. Scallon, Ann Cai, Michael Naso
-
Patent number: 7425330Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: October 16, 2006Date of Patent: September 16, 2008Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7423129Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: September 13, 2007Date of Patent: September 9, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20080214789Abstract: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNF?-inhibitors.Type: ApplicationFiled: February 19, 2008Publication date: September 4, 2008Inventor: Sunil Agarwal
-
Patent number: 7416729Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: June 18, 2007Date of Patent: August 26, 2008Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7411049Abstract: Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cells.Type: GrantFiled: August 11, 2006Date of Patent: August 12, 2008Assignee: University of DelawareInventors: Melinda K. Duncan, Xiaoren Chen, William Cain
-
Patent number: 7404955Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: August 2, 2005Date of Patent: July 29, 2008Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7405277Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.Type: GrantFiled: May 27, 2004Date of Patent: July 29, 2008Assignee: Biogen Idec MA Inc.Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber